Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.54 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.54 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.47 |
| ▸ | MAP2K3 | P46734 | 2/20 | 0.46 |
| ▸ | CCNC | P24863 | 7/20 | 0.45 |
| ▸ | CDK8 | P49336 | 7/20 | 0.45 |
| ▸ | IKBKB | O14920 | 2/20 | 0.44 |
| ▸ | CHUK | O15111 | 2/20 | 0.44 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.44 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | EIF4E | P06730 | 1/20 | 0.40 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30292682 | 1.00 | MKNK1 (0.54) | MKNK1MKNK2CHEK2MAP2K3CCNC | |
| SCHEMBL231896 | 0.87 | MKNK1 (0.56) | MKNK1MKNK2CHEK2MAP2K3IKBKB | |
| SCHEMBL4560363 | 0.85 | MKNK1 (0.50) | MKNK1MKNK2IKBKBCHUKEIF4E | |
| SCHEMBL28960474 | 0.84 | MKNK1 (0.61) | MKNK1MKNK2CHEK2IKBKBCHUK | |
| SCHEMBL30165669 | 0.84 | MKNK1 (0.56) | MKNK1MKNK2CHEK2IKBKB | |
| SCHEMBL29594571 | 0.84 | MKNK1 (0.56) | MKNK1MKNK2CHEK2IKBKB | |
| SCHEMBL28226910 | 0.84 | MKNK1 (0.76) | MKNK1MKNK2CHEK2CDK8IKBKB | |
| SCHEMBL2572631 | 0.84 | MKNK1 (0.56) | MKNK1MKNK2CHEK2IKBKB | |
| SCHEMBL30039764 | 0.84 | MKNK1 (0.61) | MKNK1MKNK2CHEK2IKBKBCHUK | |
| SCHEMBL28279600 | 0.84 | KDM4E (0.53) | MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4225310-A1 | HETEROARYL AMIDE INHIBITORS OF CD38 | Napa Therapeutics Ltd. (VG) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022077034-A1 | HETEROARYL AMIDE INHIBITORS OF CD38 | NAPA THERAPEUTICS LTD. (VG) | 2022-04-14 | — | — | WO | disclosed |
| CN-110520130-A | USL-311 for treating cancer | PROXIMAGEN GROUP LTD | 2019-11-29 | — | — | CN | disclosed |
| EP-3355871-A1 | COMBINATIONS OF THE BTK INHIBITOR GS-4059 WITH INHIBITORS SELECTED FROM A JAK, ASK1, BRD AND/OR MMP9 INHIBITOR TO TREAT CANCER, ALLERGIC DISORDERS, AUTOIMMUNE DISEASES OR INFLAMMATORY DISEASES | Gilead Sciences, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| CN-107438437-A | Novel treatment for cancer | 普罗克斯马根有限公司 | 2017-12-05 | — | — | CN | disclosed |
| EP-2627649-A1 | CXCR4 RECEPTOR ANTAGONISTS | Proximagen Limited (GB) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012049277-A1 | CXCR4 RECEPTOR ANTAGONISTS | PROXIMAGEN LTD (GB) | 2012-04-19 | — | — | WO | disclosed |